Neogen Reports Mixed Q3 2026 Results Amid Strategic Overhaul
Event summary
- Neogen's Q3 2026 revenue declined 4.4% YoY to $211.2M, with Food Safety segment up 2.6% and Animal Safety down 20.1%.
- Company raised FY2026 revenue guidance to $857M-$860M from $845M-$855M, maintaining adjusted EBITDA guidance at ~$175M.
- Neogen agreed to sell its Genomics business to Zoetis for $160M, expecting net proceeds of ~$140M post-closing costs.
- CEO Mike Nassif cited supply chain disruptions in Animal Safety and progress in Food Safety segment growth.
- Adjusted EBITDA margin improved to 22.8% from 22.0% YoY due to cost-saving initiatives.
The big picture
Neogen's mixed Q3 results reflect ongoing strategic transformation, with Food Safety showing resilience amid Animal Safety disruptions. The Zoetis deal signals a portfolio focus shift, while cost controls and improved EBITDA margins demonstrate operational discipline. The company's ability to navigate supply chain issues and complete its manufacturing transition will be critical for long-term positioning in the food safety and animal health markets.
What we're watching
- Segment Performance
- Whether Neogen can sustain Food Safety growth while addressing Animal Safety supply chain challenges.
- Divestiture Impact
- How the $160M Genomics sale to Zoetis will affect Neogen's strategic focus and financial flexibility.
- Execution Risk
- The pace at which Neogen implements its go-to-market strategy review and Petrifilm manufacturing transition.
Related topics